Immunocore (IMCR) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maze Therapeutics (MAZE) has outperformed Immunocore (IMCR) over the past year, losing 5.8% versus a loss of 14.1%. Immunocore is the larger company by market cap ($1.52 billion vs $1.42 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | MAZE |
|---|---|---|
| Share price | $29.56 | $25.51 |
| Market cap | $1.52B | $1.42B |
| 1-day change | +0.49% | -2.84% |
| YTD return | -15.27% | -36.64% |
| 1-year return | -14.06% | -5.78% |
| 5-year return | -22.61% | — |
| EPS (TTM) | $-0.36 | $-2.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $53.65 |
| 52-week low | $27.56 | $21.95 |
| Distance from 52-week high | -27.41% | -52.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.25% | +141.13% |
| Average volume | 447.09K | 560.26K |
| Shares outstanding | 51.50M | 55.55M |
| Employees | 524 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
IMCR vs MAZE FAQ
Which is bigger, Immunocore or Maze Therapeutics?
Immunocore (IMCR) is larger, with a market capitalization of $1.52B compared with $1.42B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, IMCR or MAZE?
MAZE returned -5.78% over the past 12 months, compared with -14.06% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.